Alterity Therapeutics Limited (ATHE)
NASDAQ: ATHE · Real-Time Price · USD
4.210
+0.100 (2.43%)
At close: Sep 11, 2026, 4:00 PM EDT
4.050
-0.160 (-3.80%)
After-hours: Sep 11, 2026, 7:30 PM EDT
Alterity Therapeutics Revenue
In the fiscal year ending June 30, 2026, Alterity Therapeutics had annual revenue of 3.61M AUD, down -52.76%. Alterity Therapeutics had revenue of 806.59K in the half year ending June 30, 2026, a decrease of -61.93%.
Revenue (ttm)
3.61M AUD
Revenue Growth
-52.76%
P/S Ratio
28.86
Revenue / Employee
328,183 AUD
Employees
11
Market Cap
72.09M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 3.61M | -4.03M | -52.76% |
| Jun 30, 2025 | 7.64M | 3.62M | 90.12% |
| Jun 30, 2024 | 4.02M | 102.95K | 2.63% |
| Jun 30, 2023 | 3.92M | -1.21M | -23.56% |
| Jun 30, 2022 | 5.12M | 638.30K | 14.23% |
| Jun 30, 2021 | 4.49M | 4.36M | 3,554.58% |
| Jun 30, 2020 | 122.73K | -4.83M | -97.52% |
| Jun 30, 2019 | 4.95M | 1.83M | 58.40% |
| Jun 30, 2018 | 3.13M | 103.10K | 3.41% |
| Jun 30, 2017 | 3.02M | -1.87M | -38.27% |
| Jun 30, 2016 | 4.90M | -1.60M | -24.61% |
| Jun 30, 2015 | 6.49M | -1.71M | -20.89% |
| Jun 30, 2014 | 8.21M | 3.57M | 76.94% |
| Jun 30, 2013 | 4.64M | 2.11M | 83.56% |
| Jun 30, 2012 | 2.53M | 2.36M | 1,451.38% |
| Jun 30, 2011 | 162.92K | -52.09K | -24.23% |
| Jun 30, 2010 | 215.01K | -213.19K | -49.79% |
| Jun 30, 2009 | 428.19K | -62.92K | -12.81% |
| Jun 30, 2008 | 491.11K | -16.32K | -3.22% |
| Jun 30, 2007 | 507.44K | -542.85K | -51.69% |
| Jun 30, 2006 | 1.05M | -1.60M | -60.41% |
| Jun 30, 2005 | 2.65M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Champions Oncology | 59.43M |
| Gossamer Bio | 53.29M |
| BioStem Technologies | 34.59M |
| NeurAxis | 5.32M |
| Nutriband | 1.62M |
ATHE News
- 19 hours ago - Alterity Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 8 days ago - Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026 - GlobeNewsWire
- 15 days ago - Alterity Therapeutics Annual report: H2 2026 - Filings
- 25 days ago - Alterity Therapeutics granted new patent for ATH434 - TheFly
- 4 weeks ago - Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434 - GlobeNewsWire
- 4 weeks ago - Alterity Therapeutics Transcript: Canaccord Genuity's 46th Annual Growth Conference - Transcripts
- 4 weeks ago - Alterity Therapeutics (ATHE) Rated Buy by Craig-Hallum Amid Phase 3 Trial Optimism - GuruFocus
- 4 weeks ago - Craig-Hallum bullish on Alterity Therapeutics, initiates with a Buy - TheFly